IL248621B - Formulations and methods for vaginal administration of antiprogestins - Google Patents

Formulations and methods for vaginal administration of antiprogestins

Info

Publication number
IL248621B
IL248621B IL248621A IL24862116A IL248621B IL 248621 B IL248621 B IL 248621B IL 248621 A IL248621 A IL 248621A IL 24862116 A IL24862116 A IL 24862116A IL 248621 B IL248621 B IL 248621B
Authority
IL
Israel
Prior art keywords
antiprogestins
formulations
methods
vaginal delivery
vaginal
Prior art date
Application number
IL248621A
Other languages
English (en)
Hebrew (he)
Other versions
IL248621A0 (en
Original Assignee
Allergan Pharmaceuticals Int Ltd
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Pharmaceuticals Int Ltd, Repros Therapeutics Inc filed Critical Allergan Pharmaceuticals Int Ltd
Publication of IL248621A0 publication Critical patent/IL248621A0/en
Publication of IL248621B publication Critical patent/IL248621B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL248621A 2014-05-05 2016-10-30 Formulations and methods for vaginal administration of antiprogestins IL248621B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461988766P 2014-05-05 2014-05-05
PCT/US2015/027122 WO2015171319A1 (en) 2014-05-05 2015-04-22 Formulations and methods for vaginal delivery of antiprogestins

Publications (2)

Publication Number Publication Date
IL248621A0 IL248621A0 (en) 2017-01-31
IL248621B true IL248621B (en) 2020-09-30

Family

ID=54392846

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248621A IL248621B (en) 2014-05-05 2016-10-30 Formulations and methods for vaginal administration of antiprogestins

Country Status (9)

Country Link
US (3) US10064815B2 (enExample)
EP (1) EP3139908A4 (enExample)
JP (2) JP6591447B2 (enExample)
CN (2) CN106232107B (enExample)
AU (1) AU2015256473B2 (enExample)
CA (1) CA2948287A1 (enExample)
IL (1) IL248621B (enExample)
MX (2) MX384159B (enExample)
WO (1) WO2015171319A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250979T1 (hr) * 2017-04-14 2025-10-24 Capsugel Belgium Nv Pululan kapsule
US10857151B1 (en) 2020-02-21 2020-12-08 Villya LLC Treatment of female genital schistosomiasis
US20220047506A1 (en) 2020-08-12 2022-02-17 Villya LLC Praziquantel Formulations
WO2024158694A1 (en) 2023-01-23 2024-08-02 Villya LLC Compositions and methods for improving the solubility of erectile dysfunction therapeutics
EP4417192A1 (en) * 2023-02-17 2024-08-21 meliodys medical UG Medical device, kit, method, and anti-inflammatory substance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070516A1 (en) 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
JP2005507874A (ja) * 2001-08-29 2005-03-24 ユーエムディー， インコーポレイテッド 癌治療のための化学療法剤及び膜流出システム阻害剤の経膣送達
US7417013B2 (en) * 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
EP1593376A1 (en) * 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
EP2144601A4 (en) * 2007-04-05 2012-10-10 Univ Kansas RAPID DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULANE
KR101662186B1 (ko) * 2007-11-02 2016-10-04 애크럭스 디디에스 피티와이 리미티드 경피 전달 시스템
MX2012010327A (es) * 2010-03-22 2012-11-16 Repros Therapeutics Inc Composiciones y metodos para la administracion no toxica de antiprogestinas.
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2782584B1 (en) * 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
CA2872644A1 (en) * 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins

Also Published As

Publication number Publication date
AU2015256473A1 (en) 2016-11-17
MX2016014256A (es) 2017-02-06
JP6796693B2 (ja) 2020-12-09
CN111840246A (zh) 2020-10-30
CA2948287A1 (en) 2015-11-12
EP3139908A4 (en) 2018-05-16
EP3139908A1 (en) 2017-03-15
US10064815B2 (en) 2018-09-04
US20180325810A1 (en) 2018-11-15
MX384159B (es) 2025-03-14
IL248621A0 (en) 2017-01-31
JP6591447B2 (ja) 2019-10-16
AU2015256473B2 (en) 2018-07-12
HK1232125A1 (zh) 2018-01-05
CN106232107B (zh) 2020-06-05
US20200222315A1 (en) 2020-07-16
US10555900B2 (en) 2020-02-11
CN106232107A (zh) 2016-12-14
WO2015171319A1 (en) 2015-11-12
MX2020005921A (es) 2020-08-20
JP2019194271A (ja) 2019-11-07
US20170181965A1 (en) 2017-06-29
JP2017514851A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
IL265590B (en) Formulations and methods for keratin treatment
LT3386484T (lt) Gydomųjų medžiagų sudėtis ir pristatymo metodai
ZA201702634B (en) Therapeutic agent delivery device
IL247177B (en) Intraocular implant delivery device and methods for its use
IL253123B (en) Preparations for administration through the skin and their uses
EP3125866A4 (en) Refillable drug delivery devices and methods of use thereof
SG11201609966SA (en) Drug delivery system and method of use
IL252172B (en) Expandable drug delivery devices and methods of use
IL247795A0 (en) tco couplings and methods for shipping medical materials
PL3234107T3 (pl) Limfocyty b do dostarczania in vivo środków terapeutycznych
HUE055460T2 (hu) Készítmények és módszerek a célzott citokin bejuttatására
EP3183026A4 (en) Implants for localized drug delivery and methods of use thereof
SG11201607035YA (en) Methods and compositions for personalized pain management
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
SG11201607600TA (en) Vaginal composition and use thereof
IL248621A0 (en) Formulations and methods for vaginal administration of antiprogestins
SG11201610383YA (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
GB201406172D0 (en) Therapy and pharmaceutical composition
PT3519025T (pt) Dispositivo de administração
IL259884A (en) Medicinal estradiol compositions for vaginal insertion and methods of using them
IL249121A0 (en) Intravaginal formulations containing gnrh
GB201419559D0 (en) Therapeutic compositions and methods
GB201408738D0 (en) Components and methods for formulation of components

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed